1 Stock Up by 63% This Year That Could Double, According to Wall Street

Core Insights - Intellia Therapeutics is collaborating with Regeneron Pharmaceuticals to develop two gene-editing therapies, nex-z for ATTR amyloidosis and lonvo-z for hereditary angioedema (HAE) [1][4][5] Group 1: Product Development - Nex-z targets transthyretin (ATTR) amyloidosis, a disease caused by abnormal protein buildup in the heart, with ongoing phase 3 studies for both cardiomyopathy and hereditary forms [1] - Lonvo-z is an investigational treatment for hereditary angioedema, aiming to potentially cure the disease with a single treatment course [4] - Intellia has initiated a phase 3 study for lonvo-z, with results expected next year and plans to submit a regulatory application in the second half of 2026 [3][4] Group 2: Market Potential - Intellia estimates that lonvo-z could generate approximately $5 billion in sales by 2028, with an estimated 150,000 patients with HAE worldwide [2][5] - For nex-z, the company anticipates a market opportunity of $12 billion in sales by 2028, targeting subsets of the 50,000 patients with hereditary ATTR amyloidosis and a larger population of 200,000 to 500,000 patients with wild-type ATTR amyloidosis [7] Group 3: Financial Outlook - Intellia's current market capitalization is around $2 billion, with projections suggesting it could double within a year and reach approximately $5 billion by late 2027, assuming sales estimates are met [9] - The company’s average price target of $34.64 implies an upside of nearly 100% from current levels, indicating significant growth potential [5][6] Group 4: Investment Considerations - Intellia has $630.5 million in cash as of the end of Q2, expected to last until early 2027, providing a financial buffer for ongoing development [11] - The stock has risen by 63% this year, reflecting substantial clinical progress and analyst optimism regarding future performance [6][12]